Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

MRNS Marinus Pharmaceuticals Inc

0,3299

0,0076 (2,36%)

23 Nov 2024 - Geschlossen

Verzögert um 15 Minuten

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Marinus Pharmaceuticals Charts.

Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Marinus Pharmaceuticals Charts.

News Marinus Pharmaceuticals Inc

Form 8-K - Current report
Freitag 15 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Freitag 15 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 12 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 12 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Dienstag 12 November 2024 (2 Wochen vor) • Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Samstag 2 November 2024 (3 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 24 Oktober 2024 (1 Monat vor) • Edgar (US Regulatory)

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Donnerstag 24 Oktober 2024 (1 Monat vor) • Business Wire

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
Donnerstag 17 Oktober 2024 (1 Monat vor) • Business Wire

Weitere Marinus Pharmaceuticals Inc News-Artikel

Deutsche Telekom (QX)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen